Author

N. V. Dharia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

K. Stegmaier· 2 shared A. Berezovskaya· 1 shared A. Conway· 1 shared A. D. Durbin· 1 shared A. Letai· 1 shared A. Robichaud· 1 shared A. T. Look· 1 shared B. Adane· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

K. Stegmaier

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

STAT3 cooperates with the core transcriptional regulatory circuitry to drive MYC expression and oncogenesis in anaplastic large cell lymphoma

N. Prutsch, S. He, A. Berezovskaya, A. D. Durbin, N. V. Dharia, K. Stegmaier, J. D. Matthews, L. Hare, S. D. Turner, L. Kenner, O. Merkel, R. A. Young, B. J. Abraham, A. T. Look, M. W. Zimmerman

This study identifies STAT3's role in driving MYC expression and oncogenesis in ALCL by cooperating with a core transcriptional regulatory circuit.

bioRxiv · Aug 31, 2022 · PreprintCancer Biology

An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML

S. Lin, C. Larrue, B. K. A. Seong, N. V. Dharia, M. Kuljanin, C. Wechsler, G. Kugener, A. Robichaud, A. Conway, T. N. Mashaka, S. Mouche, B. Adane, J. Ryan, J. D. Mancias, S. T. Younger, , K. Stegmaier

This study identifies novel therapeutic targets for AML using an in vivo CRISPR screening platform, revealing SLC5A3 as a metabolic vulnerability and MARCH5 as an apoptosis regulator.

bioRxiv · Dec 28, 2020Cancer Biology